vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v18i2.2012vsp-2075Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWВакцинация против пневмококковой инфекции пациентов с системным ювенильным идиопатическим артритом, получающих биологическую терапию: обзор международного опытаPneumococcal Vaccine in Patients with Systemic Juvenile Idiopathic Arthritis Receiving Biologic Therapy: International Practice Reviewhttps://orcid.org/0000-0002-3874-4721АлексееваЕ. И.AlekseevaEkaterina I.

Москва

Moscow

ВаньковаД. Д.Van’kovaDariya D.

аспирант ревматологического отделения НМИЦ здоровья детей

119991, Москва, Ломоносовский пр-т, д. 2/62, тел.: +7 (499) 134-14-94

Moscow

DD1201@mail.ruСолошенкоМ. А.SoloshenkoMargarita A.

Москва

Moscow

ДворяковскаяТ. М.DvoryakovskayaTatyana M.

Москва

Moscow

ИсаеваК. Б.IsaevaKseniya B.

Москва

Moscow

ДенисоваР. В.DenisovaRina V.

Москва

Moscow

МамутоваА. В.MamutovaAnna V.

Москва

Moscow

ЧомахидзеА. М.ChomahidzeAleksandra M.

Москва

Moscow

МаянскийН. А.MayanskiyNikolay A.

Москва

Moscow

ТкаченкоН. Е.TkachenkoNatalya E.

Москва

Moscow

Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University (Sechenov University)Russian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation201923062019182101108Copyright © Алексеева Е.И., Ванькова Д.Д., Солошенко М.А., Дворяковская Т.М., Исаева К.Б., Денисова Р.В., Мамутова А.В., Чомахидзе А.М., Маянский Н.А., Ткаченко Н.Е., 20192019Алексеева Е.И., Ванькова Д.Д., Солошенко М.А., Дворяковская Т.М., Исаева К.Б., Денисова Р.В., Мамутова А.В., Чомахидзе А.М., Маянский Н.А., Ткаченко Н.Е.Alekseeva E.I., Van’kova D.D., Soloshenko M.A., Dvoryakovskaya T.M., Isaeva K.B., Denisova R.V., Mamutova A.V., Chomahidze A.M., Mayanskiy N.A., Tkachenko N.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2075

В обзоре обобщен международный опыт иммунизации против пневмококка пациентов с системным ювенильным идиопатическим артритом (сЮИА), получающих биологическую терапию. Показана высокая эффективность и безопасность пневмококковых вакцин у детей с сЮИА. Многочисленные исследования демонстрируют адекватный иммунный ответ после вакцинации, в том числе на фоне терапии генно-инженерными биологическими препаратами. Профилактика пневмококковой инфекции у больных сЮИА снижает риск развития осложненных форм пневмококковых заболеваний.

International practice of immunization against pneumococcus in patients with systemic juvenile idiopathic arthritis (SJIA) receiving biological therapy is generalized in this review. High efficiency and safety of pneumococcal vaccines in children with SJIA is presented. Numerous researches show the adequate immune response after vaccination as well as alongside with genetically engineered biologic drugs therapy. Prevention of pneumococcal disease in patients with SJIA reduces the risk of development of pneumococcal diseases severe complications.

детисистемный ювенильный идиопатический артритвакцинацияпневмококковая инфекцияпрофилактикаэффективностьбезопасностьбиологическая терапиягенно-инженерные биологические препаратыchildrensystemic juvenile idiopathic arthritisvaccinationpneumococcal diseasepreventionefficiencysafetybiologic therapygenetically engineered biologic drugsReferenceswho.int [Internet]. Health topics: Pneumonia. Available from: https://www.who.int/en/news-room/fact-sheets/detail/pneumonia.who.int [Internet]. Health topics: Pneumonia. Available from: https://www.who.int/en/news-room/fact-sheets/detail/pneumonia.Медико-демографические показатели Российской Федерации в 2016 году. Стат. справочник. — М., 2017. — 254 c.Medikodemograficheskie pokazateli Rossijskoj Federatsii v 2016 godu. Stat. spravochnik. Moscow: 2017. 254 р. (In Russ).World Health Organization [Internet]. Measuring impact of streptococcus pneumoniae and haemophilus influenzae type b conjugate vaccination [cited 2017 August 12]. WHO; 2017. Available from: http://www.who.int/tb/publications/global_report/en/.World Health Organization [Internet]. Measuring impact of streptococcus pneumoniae and haemophilus influenzae type b conjugate vaccination [cited 2017 August 12]. WHO; 2017. Available from: http://www.who.int/tb/publications/global_report/en/.cdc.gov [Internet]. Pneumococcal disease. Surveillance and reporting. Available from: https://www.cdc.gov/pneumococcal/surveillance.html.cdc.gov [Internet]. Pneumococcal disease. Surveillance and reporting. Available from: https://www.cdc.gov/pneumococcal/surveillance.html.Kasper DL, Fauci АS, Hauser SL, et al. Harrison’s manual of medicine. Harrison’s principles of internal medicine 19th ed. New York: McGraw Hill Education Medical; 2016.Kasper DL, Fauci АS, Hauser SL, et al. Harrison’s manual of medicine. Harrison’s principles of internal medicine 19th ed. New York: McGraw Hill Education Medical; 2016.Баранов А.А., Намазова-Баранова Л.С., Брико Н.И., и др. Вакцинопрофилактика пневмококковой инфекции у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 3. — С. 200–211. doi: 10.15690/pf.v15i3.1899.Baranov AA, Namazova-Baranova LS, Brico NI, et al. Vaccinal prevention of pneumococcal infection in children. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2018; 15(3):200–211. (In Russ). doi: 10.15690/pf.v15i3.1899.O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi: 10.1016/S0140-6736(09)61204-6.O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. doi: 10.1016/S0140-6736(09)61204-6.Schrag SJ, Beall B, Dowell S; World Health Organization. Communicable diseases cluster. Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance. WHO; 2001. Available from: http://www.who.int/iris/handle/10665/66846.Schrag SJ, Beall B, Dowell S; World Health Organization. Communicable diseases cluster. Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance. WHO; 2001. Available from: http://www.who.int/iris/handle/10665/66846.Rаkоczi Е, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3(2):e000484. doi: 10.1136/rmdopen-2017-000484.Rаkоczi Е, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017;3(2):e000484. doi: 10.1136/rmdopen-2017-000484.Pinheiro FA, Souza DC, Sato EI. A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 2015;42(12): 2221–2228. doi: 10.3899/jrheum.150166.Pinheiro FA, Souza DC, Sato EI. A study of multiple causes of death in rheumatoid arthritis. J Rheumatol. 2015;42(12): 2221–2228. doi: 10.3899/jrheum.150166.Таточенко В.К., Озерецковский Н.А. Иммунопрофилактика-2018. Cправочник. 13-е изд., расш. — М.: Боргес; 2018. — 274 с.Tatochenko VK, Ozeretskovskii NA. Immunoprofilaktika-2018. Spravochnik.13th ed., enlarged. Moscow: Borges; 2018. 274 p. (In Russ).Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. PubFacts. 2016;41(7):426–436.Ventola CL. Immunization in the United States: recommendations, barriers, and measures to improve compliance: part 1: childhood vaccinations. PubFacts. 2016;41(7):426–436.WHO/UNICEF. Ending preventable child deaths from pneumonia and diarrhoea by 2025. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). 2013.WHO/UNICEF. Ending preventable child deaths from pneumonia and diarrhoea by 2025. The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD). 2013.Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi: 10.1086/648593.Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. doi: 10.1086/648593.Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238. doi: 10.1016/j.vaccine.2013.10.032.Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238. doi: 10.1016/j.vaccine.2013.10.032.cdc.gov [Internet]. Pneumococcal disease — global pneumooccal disease and vaccine. Available from: https://www.cdc.gov/pneumococcal/global.html.cdc.gov [Internet]. Pneumococcal disease — global pneumooccal disease and vaccine. Available from: https://www.cdc.gov/pneumococcal/global.html.Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018;36(50):7744–7752. doi: 10.1016/j.vaccine.2018.05.026.Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018;36(50):7744–7752. doi: 10.1016/j.vaccine.2018.05.026.Приказ Министерства здравоохранения РФ № 125н от 21 марта 2014 г. «Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям», с изменениями и дополнениями от 16 июня 2016 г., 13 апреля 2017 г. Доступно по: http://base.garant.ru/191961/. Ссылка активна на 10.12.2018.The order of the Ministry of Health № 125n ot 21 marta 2014 g. «Ob utverzhdenii natsional’nogo kalendarya profilakticheskikh privivok i kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam» (s izmeneniyami i dopolneniyami) dated 16 June 2016, 13 April 2017. (In Russ). Доступно по: http://base.garant.ru/191961/. Ссылка активна на 10.12.2018.Брико Н.И., Цапкова Н.Н., Сухова В.А., и др. Эпидемиологическая оценка первых результатов национальной программы иммунизации детей раннего возраста против пневмококковой инфекции в России // Эпидемиология и вакцинопрофилактика. — 2017. — Т. 16. — № 5. — С. 16–21. doi: 10.31631/2073-3046-2017-16-5-16-21.Brico NI, Tsapkova NN, Sukhova VA, et al. Epidemiological assessment of the first results of the national program of immunization of young children against pneumococcal infection in Russia. Epidemiology Vaccinal Prevention. 2017;16(5):16–21. (In Russ). doi: 10.31631/2073-3046-2017-16-5-16-21.Филатов Н.Н., Костинов М.П., Елагина Т.Н., и др. Факторы, влияющие на охват вакцинацией против пневмококковой инфекции детей первого года жизни на начальных этапах вакцинации // Эпидемиология и вакцинопрофилактика. — 2017. — Т. 16. — № 3. — С. 78–83. doi: 10.31631/2073-3046-2017-16-3-78-83.Filatov NN, Kostinov MP, Elagina TN, et al. Factors that Influence the coverage of vaccination against pneumococcal infections of children up to 1 year old of age at the starting phase of vaccination. Epidemiology Vaccinal Prevention. 2017;16(3):78–83. (In Russ). doi: 10.31631/2073-3046-2017-16-3-78-83.Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318. doi: 10.1093/cid/cit816.Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318. doi: 10.1093/cid/cit816.Баранов А.А., Намазова-Баранова Л.С., Таточенко В.К. Научное обоснование вакцинации детей с отклонениями в состоянии здоровья // Педиатрическая фармакология. — 2010. — Т. 7. — № 2. — С. 6–24.Baranov AА, Namazova-Baranova LS, Tatochenko VK. Scientific justification for vaccination of children with health disturbances. Pediatric pharmacology. 2010;7(2): 6–24. (In Russ).Никитюк Н.Ф., Глущенко В.А., Панин И.В. Организация иммунопрофилактики лиц с нарушениями в состоянии здоровья // БИОпрепараты. Профилактика, диагностика, лечение. — 2016. — Т. 16. — № 1. — С. 35–42. doi: 10.30895/2221-996X-2016-16-1-35-42.Nikityuk NF, Glushchenko VA, Panin IV. Scientific and methodical approaches to organizing and conducting immunization in patients with health disorders. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(1):35–42. (In Russ). doi: 10.30895/2221-996X-2016-16-1-35-42.Davies HD; Committee on infectious diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209.Davies HD; Committee on infectious diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209.Subesinghe S, Rutherford AI, Ibrahim F, et al. A large twocentre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi: 10.1186/s12891-016-1187-4.Subesinghe S, Rutherford AI, Ibrahim F, et al. A large twocentre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2016;17:322. doi: 10.1186/s12891-016-1187-4.Симонова Е.Ю., Полевиченко Е.В. Характеристика внутрибольничного регистра детей с аспленией, проживающих в Ростовской области, и анализ охвата их вакцинацией против пневмококковой инфекции // Вестник Российского университета дружбы народов. Серия «Медицина». — 2010. — № 4. — С. 456–458.Simonova EY, Polevichenko EV. The characteristic of the hospital register of children with аsplenia, living in the Rostov region and the estimation of its role in the prophylactic of the pneumococcal infection. Vestnik Rossijskogo universiteta druzhby narodov. Seriya «Meditsina». 2010;(4): 456–458. (In Russ).Белов Б.С., Наумцева М.С., Тарасова Г.М. Вакцинация в ревматологии: эволюция взглядов на проблему // Медицинский совет. — 2017. — № 5. — С. 142–147. doi: 10.21518/2079-701X-2017-5-142-147.Belov BS, Naumtseva MS, Tarasova GM. Vaccination in rheumatology: evolution of views on the problem. Meditsinskij sovet. 2017;(5):142–147. (In Russ). doi: 10.21518/2079-701X-2017-5-142-147.Cassidy JT, Petty RE Laxer R, Lindsley C. Textbook of pediatric rheumatology. 6th Edition. Elsevier Science,2010. 800 р.Cassidy JT, Petty RE Laxer R, Lindsley C. Textbook of pediatric rheumatology. 6th Edition. Elsevier Science,2010. 800 р.Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27. doi: 10.1016/j.jaci.2015.10.023.Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19–27. doi: 10.1016/j.jaci.2015.10.023.Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015; 386(9990):258–265. doi: 10.1016/S0140-6736(14)61704-9.Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015; 386(9990):258–265. doi: 10.1016/S0140-6736(14)61704-9.Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.Keyser FD. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.Maddur MS, Vani J, Lacroix-Desmazes S, et al. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2010; 6(11):e1001077. doi: 10.1371/journal.ppat.1001077.Maddur MS, Vani J, Lacroix-Desmazes S, et al. Autoimmunity as a predisposition for infectious diseases. PLoS Pathog. 2010; 6(11):e1001077. doi: 10.1371/journal.ppat.1001077.Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387–397. doi: 10.1177/1759720X12455960.Yokota S, Tanaka T, Kishimoto T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis. 2012;4(6):387–397. doi: 10.1177/1759720X12455960.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903–908. doi: 10.1016/j.vaccine.2016.12.068.Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35(6):903–908. doi: 10.1016/j.vaccine.2016.12.068.Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.Юношеский артрит с системным началом. Клинические рекомендации [интернет]. — М.: Союз педиатров России; 2016. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/58. Ссылка активна на 12.02.2019.Yunosheskij artrit s sistemnym nachalom. Klinicheskie rekomendatsii [Internet]. Moscow: Soyuz pediatrov Rossii; 2016. (In Russ). Доступно по: http://cr.rosminzdrav.ru/#!/recomend/58. Ссылка активна на 12.02.2019.Гатторно М. Аутовоспалительные заболевания у детей // Вопросы современной педиатрии. — 2014. — Т. 13. — № 2. — С. 55–64. doi.org/10.15690/vsp.v13i2.973.Gattorno M. Autoinflammatory diseases in children (The Lecture from 18th of September 2013, Conference «Topical Problems of Diagnostics and Treatment of Juvenile Rheumatoid Arthritis»; 18–20 of September, 2013, St. Petersburg). Current Pediatrics. 2014;13(2):55–64. (In Russ). doi.org/10.15690/vsp.v13i2.973.Bracaglia C, Prencipe G, De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15(1):5. doi: 10.1186/s12969-016-0130-4.Bracaglia C, Prencipe G, De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15(1):5. doi: 10.1186/s12969-016-0130-4.Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4): 493–500. doi: 10.1080/14740338.2017.1303479.Machado SH, Xavier RM. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2017;16(4): 493–500. doi: 10.1080/14740338.2017.1303479.Roszkiewicz J, Orczyk K, Smolewska E. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis — singlecentre experience. Reumatologia. 2018;56(5):279–284.Roszkiewicz J, Orczyk K, Smolewska E. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis — singlecentre experience. Reumatologia. 2018;56(5):279–284.Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125–135. doi: 10.2147/AHMT.S109495.Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125–135. doi: 10.2147/AHMT.S109495.De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7(1):77–87. doi: 10.2174/157339711794474620.Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016;16(6):46. doi: 10.1007/s11882-016-0624-7.Henrickson SE, Ruffner MA, Kwan M. Unintended immunological consequences of biologic therapy. Curr Allergy Asthma Rep. 2016;16(6):46. doi: 10.1007/s11882-016-0624-7.Burke RA, White ND. Biologic disease-modifying antirheumatic drugs [Internet]. PSAP; 2014. Available from: https://www.accp.com/docs/bookstore/psap/p14b2_m1ch.pdf.Burke RA, White ND. Biologic disease-modifying antirheumatic drugs [Internet]. PSAP; 2014. Available from: https://www.accp.com/docs/bookstore/psap/p14b2_m1ch.pdf.Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17:66. doi: 10.1007/s11926-015-0542-z.Horneff G. Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep. 2015;17:66. doi: 10.1007/s11926-015-0542-z.gene.com [Internet]. Medication Guide for tocilizumab. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf.gene.com [Internet]. Medication Guide for tocilizumab. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf.Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258–267. doi: 10.1080/14397595.2018.1546357.Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258–267. doi: 10.1080/14397595.2018.1546357.Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/kew370.Moots RJ, Sebba A, Rigby W, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology (Oxford). 2017;56(4):541–549. doi: 10.1093/rheumatology/kew370.Kostik MM, Dubko MF, Masalova VV, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44(4):417–422. doi: 10.1016/j.semarthrit.2014.09.004.Kostik MM, Dubko MF, Masalova VV, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44(4):417–422. doi: 10.1016/j.semarthrit.2014.09.004.Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195–199. doi: 10.1177/1759720X18798462.Jones G, Panova E. New insights and long-term safety of tocilizumab in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(10):195–199. doi: 10.1177/1759720X18798462.Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117–128. doi: 10.2147/OARRR.S151013.Lerkvaleekul B, Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open Access Rheumatol. 2018;10:117–128. doi: 10.2147/OARRR.S151013.Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and metaanalysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–562. doi: 10.1093/rheumatology/keq343.Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and metaanalysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552–562. doi: 10.1093/rheumatology/keq343.Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1): 56–66. doi: 10.1002/art.39399.Yun H, Xie F, Delzell E, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68(1): 56–66. doi: 10.1002/art.39399.Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatol. 2010;20(3):222–232. doi: 10.1007/s10165-010-0279-5.Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatol. 2010;20(3):222–232. doi: 10.1007/s10165-010-0279-5.Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE. Rheumatology (Oxford). 2017;56(10):1746–1754. doi: 10.1093/rheumatology/kex238.Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French registry REGATE. Rheumatology (Oxford). 2017;56(10):1746–1754. doi: 10.1093/rheumatology/kex238.Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643. doi: 10.2147/DDDT.S114532.Toplak N, Blazina S, Avcin T. The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Des Devel Ther. 2018;12:1633–1643. doi: 10.2147/DDDT.S114532.Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133. doi: 10.1007/s40259-015-0123-8.Hoy SM. Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. BioDrugs. 2015;29:133. doi: 10.1007/s40259-015-0123-8.Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthrit Rheumat. 2012;64:557–567. doi: 10.1002/art.33342.Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthrit Rheumat. 2012;64:557–567. doi: 10.1002/art.33342.Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425. doi: 10.1056/NEJMoa0810787.Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–2425. doi: 10.1056/NEJMoa0810787.Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. doi: 10.1186/s13075-017-1462-2.Horneff G, Schulz AC, Klotsche J, et al. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Res Ther. 2017;19(1):256. doi: 10.1186/s13075-017-1462-2.Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19. doi: 10.1186/s13023-015-0228-7.Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19. doi: 10.1186/s13023-015-0228-7.Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIVinfected individuals naive to pneumococcal vaccination. AIDS. 2015;29:1345–1354. doi: 10.1097/QAD.0000000000000689.Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIVinfected individuals naive to pneumococcal vaccination. AIDS. 2015;29:1345–1354. doi: 10.1097/QAD.0000000000000689.Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients — preliminary report. PLoS One. 2014;9:e114966. doi: 10.1371/journal.pone.0114966.Pasiarski M, Rolinski J, Grywalska E, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients — preliminary report. PLoS One. 2014;9:e114966. doi: 10.1371/journal.pone.0114966.Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying antirheumatic drugs. Clin Exp Rheumatol.2018;36(2):317–328.Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying antirheumatic drugs. Clin Exp Rheumatol.2018;36(2):317–328.Liang Y, Meng FY, Pan HF, Ye DQ. A literature review on the patients with autoimmune diseases following vaccination against infections. Hum Vaccin Immunother. 2015;11(9):2274–2280. doi: 10.1080/21645515.2015.1009337.Liang Y, Meng FY, Pan HF, Ye DQ. A literature review on the patients with autoimmune diseases following vaccination against infections. Hum Vaccin Immunother. 2015;11(9):2274–2280. doi: 10.1080/21645515.2015.1009337.Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44(4):271–279. doi: 10.3109/03009742.2014.984754.Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. Scand J Rheumatol. 2015;44(4):271–279. doi: 10.3109/03009742.2014.984754.Nagel J. Pneumococcal vaccination in inflammatory rheumatic disease. Antibody response and protection against infections. Lund: Lund University, Faculty of Medicine; 2018.Nagel J. Pneumococcal vaccination in inflammatory rheumatic disease. Antibody response and protection against infections. Lund: Lund University, Faculty of Medicine; 2018.Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/annrheumdis-2012-202658.Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362–1366. doi: 10.1136/annrheumdis-2012-202658.Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–516. doi: 10.3109/14397595.2013.843743.Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol. 2014;24(3):511–516. doi: 10.3109/14397595.2013.843743.Bingham CO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2014;74(5):818–822. doi: 10.1136/annrheumdis-2013-204427.Bingham CO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis. 2014;74(5):818–822. doi: 10.1136/annrheumdis-2013-204427.Jaeger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford). 2017;56(9):1484–1491. doi: 10.1093/rheumatology/kex185.Jaeger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology (Oxford). 2017;56(9):1484–1491. doi: 10.1093/rheumatology/kex185.Jeyaratnam J, Ter Haar NM, Lachmann HJ, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol Online J. 2018;16(1):19. doi: 10.1186/s12969-018-0235-z.Jeyaratnam J, Ter Haar NM, Lachmann HJ, et al. The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatr Rheumatol Online J. 2018;16(1):19. doi: 10.1186/s12969-018-0235-z.

The authors declare that there are no conflicts of interest present.